INTRODUCTION {#S1}
============

Allogeneic stem cell transplantation (allo-SCT) has been used as a highly effective curative treatment for chronic myeloid leukemia (CML) for over 30 years, in large part because of the susceptibility of this disease, particularly in its chronic phase (CP), to the graft versus leukemia (GVL) effect of the incoming donor immune system.^[@R1]-[@R5]^ As a consequence many thousands of patients with CML have received allo-SCT worldwide and are now long term survivors. The introduction of imatinib and other tyrosine kinase inhibitors (TKI) relegated the place of allo-SCT in CML to second or third line therapy in many patients, causing significant reduction in transplants for CML.^[@R6]-[@R12]^ Most CML patients who are candidates for allo-SCT in this century are patients refractory or intolerant to TKI, or those with CML more advanced than first CP.^[@R13]-[@R15]^ Relapse of CML after allo-SCT remains a current issue because relapse can be delayed, occurring even in the second decade after allo-SCT, and patients transplanted in the era of TKI treatment have a higher chance of relapse because they were transplanted for advanced or refractory disease.^[@R16]-[@R18]^ Management of relapsed CML may include DLI, TKI, chemotherapy or second allo-SCT.^[@R6]-[@R11],\ [@R19]^ With the availability of TKI and improved transplant management, the factors determining outcome after post allo-SCT relapse today are likely to differ from earlier observations. Furthermore many questions remain unanswered about the biological basis of relapse in CML -- particularly the nature of the minimal residual disease (MRD) in the progenitor cell compartment responsible for relapse^[@R20]^ and its relationship with treatment and post-relapse outcome. Recent studies showed that with advance to blastic phase the predominant leukemia initiating population in CML shifts from a lineage^−^CD34^+^CD38^−^ progenitor to a more differentiated granulocyte-macrophage progenitor.^[@R21]^ To better define factors affecting outcome after relapse in CML and to characterize the CML progenitor populations at relapse, we studied 59 patients relapsing post allo-SCT at our institute between 1993 and 2008. In 22 relapsed patients, we correlated the pattern of BCR-ABL expression in defined subpopulations of hematopoietic stem and progenitor cells with treatment response and outcome. Here we present clinical and biological parameters that were associated with post relapse outcome of CML following allo-SCT.

METHODS {#S2}
=======

Study Population {#S3}
----------------

Between September 1993 and August 2008, 109 consecutive patients with Philadelphia chromosome positive CML underwent allo-SCT from a 6/6 HLA identical sibling in successive National Heart, Lung and Blood Institute (NHLBI) institutional review board-approved protocols (93-H-0212, 97-H-0202, 97-H-0099, 00-H-0001, 01-H-0010, 02-H-0111, 03-H-0192, 04-H-0112, 06-H-0248, 07-H-0136, 09-H-0062). Written informed consent, consistent with the Helsinki Declaration, was obtained from all patients and donors.

Transplant conditioning regimen and ex-vivo T cell depletion {#S4}
------------------------------------------------------------

Ninety six patients (88%) received a myeloablative conditioning regimen with cyclophosphamide 120mg/kg +/− fludarabine 125mg/m^2^ and total body irradiation (1200 to 1360 cGy). Thirteen patients (12%) received a non-myeloablative conditioning regimen consisting of cyclophosphamide 120mg/kg and fludarabine 125mg/m^2^. Twenty seven patients (25%) received bone marrow and 82 patients (75%) received G-CSF-mobilized peripheral blood as the stem cell source. Thirteen patients (12%) given nonmyeloablative conditioning received a T-lymphocyte replete graft and 96 (88%) received a 4-log~10~ *ex-vivo* T-lymphocyte depleted graft. T cell depletion was achieved using the CellPro system (CellPro Inc., Bothel, WA) before 1999, Isolex 300i (Nexell Therapeutics Inc, Irvine, CA) from 1999 to 2006 and thereafter positive selection of CD34^+^ cells using the MiltenyiCliniMacs system (MiltenyiBiotec Inc., Auburn, CA). Cyclosporine (CSA) was used throughout for GVHD prophylaxis, with varied dose according to protocol.^[@R22]^ In addition to CSA, methotrexate and/or mycophenolate mofetil were used in T-replete graft protocols.

Clinical BCR-ABL monitoring {#S5}
---------------------------

Patients were monitored for molecular evidence of leukemia by PCR- based amplification of b2a2 and b3a2 transcripts encoding the p210 BCR-ABL fusion product. Blood samples were collected at least every three months up to 1 year post transplant, then at least annually thereafter. In all cases, RNA was extracted from peripheral blood leukocytes after ammonium chloride lysis of red cells, and cDNA was produced by reverse transcription using random hexamer primers. Before 2003, samples were assayed qualitatively using double-nested PCR to amplify BCRABL.^[@R23]^ After June 2003, a commercial real-time PCR kit (Roche, Indianapolis, IN, USA) replaced as the method to detect BCR-ABL, with G6PDH as the control gene as described previously.^[@R24]^ After June 2009, the ipsogen BCR-ABL1 Mbcr Kit (Qiagen, Valencia, CA) was used to measure BCR-ABL and the control gene ABL1. The double-nested assay and real-time BCR-ABL assays were all qualitatively comparable in sensitivity detecting BCR-ABL transcripts in K562 RNA diluted to 1: 100,000-1,000,000 in control RNA. To facilitate serial monitoring over time and to reconcile the different techniques used for BCR-ABL measurement, positive values obtained with the older assay were mathematically "converted" to units of BCRABL: ABL1 based on a good linear log-log relationship (r^2^ 0.883, p\<0.001) between values obtained in parallel measurements of 50 positive clinical samples with both assays. In this study, we defined a sample positive for BCR-ABL if a detectable band was noted in a double-nested assay, or if either of two duplicate samples generated a measurable crossing point in the real-time PCR assay. Samples were considered negative, if no BCR-ABL band or crossing point was detected and the housekeeper gene expression assay confirmed good control gene expression.^[@R25]^

Definition and management of relapse {#S6}
------------------------------------

*Chronic phase (CP)* is defined as first chronic phase, while blast crisis, accelerated phase, and second chronic phase were categorized as *advanced-phase (AP) disease*. *Molecular relapse* was defined as a detectable BCR-ABL transcript level by PCR on more than 2 consecutive occasions, requiring salvage treatments. *Hematological relapse* followed the Center for International Bone and Marrow Transplantation Registry (CIBMTR) criteria^[@R26]^. For relapsed patients, the BCR-ABL patterns were further classified into two categories. Patients who had consecutively positive BCR-ABL post relapse were categorized as *persistently positive*. Patients who remained BCRABL negative for two or more consecutive readings after initial positive readings post-transplant were categorized as *persistently negative*. *Molecular relapse* was treated with DLI with or without imatinib 400-600 mg/day. *Hematological relapse* was treated at the investigator\'s discretion with imatinib, other TKI, interferonα or second SCT as previously described.^[@R19],\ [@R27]^ *Concurrent TKI and DLI* was defined as the initiation of both treatments within 6 months of each other.

Measurement of BCR-ABL in the hematopoietic progenitor cell compartment {#S7}
-----------------------------------------------------------------------

### Cell samples {#S8}

Mononuclear cells from peripheral blood or bone marrow were isolated by density gradient centrifugation (OrganonTeknika, Durham, NC) and cryopreserved in RPMI1640 supplemented with 20% fetal calf serum and 10% dimethyl sulfoxide. After thawing, CD34^+^ cells were selected by immunomagnetic beads (MiniMACS, Miltenyi Biotech, Auburn, CA). Sample date varied between the subjects, but all samples from relapsed patients were collected when the concurrent peripheral blood showed either positive BCR-ABL or hematological relapse after the diagnosis of relapse (median time from diagnosis of relapse to sample collection was 386 days). Six patients who were on TKI alone and never received allo-SCT, served as controls **([Supplementary Table 1](#SD2){ref-type="supplementary-material"}).**

### Flow cytometry {#S9}

Fluorescence-activated cell sorting (FACS) was performed with the FACSAria sorter (BD Biosciences, San Jose, CA). Monoclonal antibodies for cell surface markers were FITC-CD38 (Beckman Coulter, Fullerton, CA), PE- lineage (Lin) markers^[@R28]^, PE-Cy5- IL3Rα, APC-CD90, APC-Cy7- or PE-Cy7-CD34 (BD Biosciences, San Jose, CA) and PE-Texas Red-CD45RA (Beckman-Coulter). CD38^+^ and CD38^−^ cells were gated off the total CD34^+^ population. Lin-CD34^+^CD38^−^ CD90^+^hematopoietic stem cells (HSC)^[@R21]^, common myeloid progenitors (CMP) Lin^−^CD34^+^CD38^+^ IL3Rα^+^CD45RA^−^ , and granulocyte-macrophage progenitors (GMP) Lin-CD34^+^CD38^+^ IL3Rα^+^CD45RA^+^ were collected (**[Supplementary Figure 1](#SD4){ref-type="supplementary-material"}**).^[@R29]^

### Real-time quantitative polymerase chain reaction (RQ-PCR) {#S10}

Total RNA was extracted from sorted CD34^+^ subpopulations using the RNeasy kit (Qiagen, Valencia, CA), and cDNA synthesized using the Advantage RT-for-PCR kit (Clontech, Mountain View, CA). ABL1 expression was used as the endogenous cDNA control.^[@R30]^ BCR-ABL transcripts were assessed according to an MRD detection assay using recommended standardized probe and primers.^[@R31]^ All reactions by RQ-PCR using the ABI PRISM 7900 system (Applied Biosystems, Foster City, CA, USA) were performed in triplicate. BCR-ABL RQ-PCR reactions consistently detected one leukemic cell in 1,000,000 non-leukemic cells.

Statistical methods {#S11}
-------------------

Patient characteristics were described by the frequencies and sample proportions and compared by the Fisher\'s exact test between subgroups. Kaplan-Meier estimates were used to estimate time-to-event distributions of overall survival (OS) post-transplant, and post relapse survival (PRS), with PRS defined as the time from first relapse until last follow up. Log-rank tests were used to compare the survival curves. For the analysis of progenitor cell compartment BCR-ABL measurement, since the timing of sample collection is not always identical to the diagnosis of relapse, we analyzed the data according to the disease status at transplant rather than the type of relapse. Also, time from sample collection to last follow up was used as a surrogate end point for PRS in this subgroup analysis. Cox proportional hazards regression models were used to examine the prognostic factors associated with PRS. Backward stepwise selection was used to determine the parsimonious multivariate models. The proportional hazards assumption is tested using the scaled Schoenfeld residuals and there was no evidence for non-proportionality in any of the models presented. All tests were two-sided and a P-value \<0.05 was used for statistical significance. Analysis was performed using the SAS statistical software (version 9.3, SAS Institute Inc., Cary, NC, USA). Graphs were created using Prism 5.03 (GraphPad Software, Inc. La Jolla, CA, USA).

RESULTS {#S12}
=======

Characteristics of relapsed patients {#S13}
------------------------------------

One hundred and nine patients received allo-SCT between 1993 and 2008. Eighty three patients (76%) were in CP at transplant and ninety-three patients (84.5%) had never received TKI prior to transplantation. Fifty-nine patients (54%) relapsed (37 molecular and 22 hematological) and the median time from transplant to relapse was 1 year (363 days, range: 16 to 3773 days). Twenty (34%) patients died, 16 (80%) following relapse, and 4 (20%) from non-relapse causes. Ten-year overall survival post-transplant was 65% in relapsed patients. The characteristics of relapsed are described in **[Table 1](#T1){ref-type="table"}.** Forty-seven (80%) patients with relapse were TKI naïve. Eighteen (30.5%) had AP at the time of transplant while 41(69.5%) were in CP.

Post relapse outcome {#S14}
--------------------

The median follow-up from relapse was 7.9 years (2899 days: range 98-5744). After salvage therapy for relapse, 26 (44.1%) patients became *persistently negative* for BCR-ABL, while 33 (55.9%) never achieved a permanent negative BCR-ABL pattern (*persistently positive*). Patient characteristics of persistently negative vs. persistently positive individuals are shown in **[Table 2](#T2){ref-type="table"}**. After relapse 34 patients (57.6%) received TKI; 42 (71.2%) received DLI; 15 (25.4%) received concurrent DLI and TKI. The 5-year post relapse survival (PRS) survival was 68%. In univariate analysis of the relationship of patient characteristics and PRS, CP disease status at first transplant, and molecular relapse, favorably influence the PRS **([Figure 1 A&B](#F1){ref-type="fig"})**. Earlier relapse post-transplant was associated with poor PRS (P\<0.001), with 5-year PRS rate of 33%, 67% and 93% for patients with diagnosis of relapse within 100 days, between 100 days to 1 years, and after one year from transplant, respectively **([Figure 1C](#F1){ref-type="fig"}).** In contrast, age at transplant, age at relapse, gender, female to male transplant, graft source, recipient CMV serostatus, donor CMV serostatus, acute GvHD, pre-transplant TKI use, DLI, or concurrent DLI with TKI had no impact on post relapse survival. Pre-transplant TKI use showed a favorable trend on PRS after stratifying by the disease status **([Figure 1D](#F1){ref-type="fig"}).** In addition, patients with a persistently positive BCR-ABL pattern had a 5-year PRS of 41% compared to 100% for persistently negative pattern (P\<0.001). In a univariate Cox model with a time-dependent covariate, the post-relapse TKI use had no effect on PRS. Multivariate analyses were performed to adjust for potential confounding factors. In the Cox regression models with backward elimination, significant factors associated with PRS were disease status, pre-transplant TKI use and time to diagnosis of relapse from transplant. These factors remained significant after controlling for age at relapse, gender, female to male transplant and graft source. Because 19/20 deaths were observed in the subgroups of patients with hematological relapse (N= 22) or persistent positive BCR-ABL (N=33), the Cox models were also performed separately for these subgroups and similar results were obtained **([Table 3](#T3){ref-type="table"}).** Interestingly, pre-transplant TKI was found to be a protective factor for longer PRS after adjusting for the disease status and time to diagnosis of relapse from transplant, especially for high risk patients with hematological relapse or persistent positive BCR-ABL.

BCR-ABL expression in progenitor cells {#S15}
--------------------------------------

To evaluate biological characteristics of CML relapse after allo-SCT, we performed BCR-ABL analysis of the hematopoietic progenitor compartment in 36 patients (22 relapsed, 8 non-relapsed patients, and 6 TKI only controls). The characteristics of these 22 relapsed patients were not significantly different from the entire relapsed cohort **([Supplementary Table 2](#SD3){ref-type="supplementary-material"})**. The distribution pattern of absolute numbers of progenitors sorted in the three compartments did not differ between relapsed and non-relapsed samples **([Figure 2A](#F2){ref-type="fig"}).** Seventy-seven percent of relapsed samples harbored BCR-ABL transcript in at least one of the progenitor cell compartments (HSC, CMP, or GMP), indicating relapse could first be detected as an expansion in any of the three progenitor compartments **([Figure 2B](#F2){ref-type="fig"})**. BCR-ABL transcripts were generally more detectable in the CMP/GMP compartment compared with the HSC group, irrespective of the time to diagnosis of relapse (**[Supplementary Figure 2](#SD5){ref-type="supplementary-material"}**) In AP, significantly higher BCRABL transcripts were detected in the CMP compartment (P\< 0.017) compared to that in CP. BCR-ABL transcripts in HSC and GMP compartments were not significantly different between AP and CP. The distribution of BCR-ABL transcript in progenitor cell compartment in each individual sample was heterogeneous according to the disease status. In 8 CP, the BCR-ABL transcript levels were detected predominantly in the HSC compartment **([Figure 3A](#F3){ref-type="fig"})**, while in 3 CP, they were detected predominantly in the CMP/GMP compartment **([Figure 3B](#F3){ref-type="fig"})**; and 5 had no detectable BCR-ABL transcripts. In contrast in 3 AP, BCR-ABL transcript levels were detected predominantly in the CMP/GMP compartment **([Figure 3C](#F3){ref-type="fig"})**, while in the other 3AP, the BCRABL transcript levels were detected predominantly in the HSC compartment **([Figure 3D](#F3){ref-type="fig"})**. Therefore, we categorized the BCR-ABL distribution pattern into either 1) non-detectable BCRABL in the progenitor cells 2) HSC predominant or 3) CMP/GMP predominant. The BCR-ABL distribution pattern in progenitor cell compartment was highly correlated with PRS (P=0.008: **[Figure 4](#F4){ref-type="fig"}).**

DISCUSSION {#S16}
==========

In this study, we explored the features that affected the outcome of 59 patients relapsing after SCT for CML. This is the first detailed clinical and biological analysis of post relapse outcome in CML in the modern therapeutic era. Unlike acute myeloid leukemia which rarely recurs after 3 years post-transplant, late relapses at prolonged intervals from SCT occur in CML.^[@R16]-[@R18]^ However little is known about the mechanisms underlying relapse of CML after transplant. It is suggested that long lived leukemia initiating progenitors of CML persist in a dormant state.^[@R32],\ [@R33]^ In this model, the GVL effect is constantly needed to hold leukemia initiating cells from causing a relapse.^[@R34]^

The characteristics of CML relapse after allo-SCT may vary depending on the status of the disease at transplant and exposure to TKI pre transplant. Of the 20 patients who died after relapse in this series, all but one died directly of leukemia. We therefore have used survival post relapse as a surrogate for treatment success. Treatment for relapse included DLI, TKI, combinations of both with or without interferon, or second transplant. We previously reported the synergy between TKI and DLI in a smaller subset of this series with a shorter follow up.^[@R19]^ While there was an early survival advantage for use of DLI in addition to TKI, this significance is lost after longer follow-up. As is well established, we found that disease status at transplant was the major factor determining survival after relapse.^[@R35]^ We also found earlier relapse from transplant, and the absence of pre-transplant TKI exposure were significantly associated with poor survival after relapse. In addition, *post-relapse* BCR-ABL pattern was highly correlated with PRS, with patients who had persistently negative BCR-ABL surviving longer than those persistently positive as reported previously.^[@R32]^ The post-hoc power analysis showed that our study has 80% power to detect a hazard ratio of 4 (or 0.25) with a two-sided significance level of 0.05, thus our study would have limited power to identify risk factors with smaller effect. Nevertheless, all factors associated with poor post relapse outcomes may be explained by the persistence of MRD. Therefore, we speculate that leukemic HSC population might be the source of MRD and the last cell population to be eradicated by GVL.

Analysis of BCR-ABL in the progenitor cell compartments permitted a further categorization of post-relapse outcome. In CP, we found that the presence of BCR-ABL expression in HSC compartment was associated with poorer outcome compared to the group with BCR-ABL expression either predominant in the GMP/CMP compartment or undetectable in any progenitor cell compartment. In AP, all patients had BCR-ABL transcript in the CMP/GMP compartment as described previously^[@R21]^, however those with the worst prognosis had a predominance of BCRABL in the HSC compartment. The underlying biology of the leukemia stem cell in AP may affect immunogenicity, rendering them more resistant to GVL in comparison to CP, thus accounting for the poorer outcome in patients who are transplanted in AP, and poorer response clinically to DLI. Alternatively, leukemia HSC susceptibility to immune attack may be similar between CP and AP. Relapse therefore arises due to the persistence of a critical number of such cells, which in our study rendered them detectable. This critical number of leukemic stem cells would, stochastically, result in a greater probability of the emergence of a cell which has developed immunological^[@R36]^ or pharmacological resistance^,[@R37]^ or both, and intrinsically also has the ability to propagate leukemia. In our study, the sample size available for the analysis of progenitor cell compartment is too small to make a conclusion, however we hope our data may encourage further research to answer these hypothesis.

In summary, while relapse of CML post allo-SCT is often considered a relatively easily treated complication with a favorable outcome, this is only true for molecular relapse in patients with CP. Our study draws attention to a significant overall mortality following relapse of CML post-transplant (5-year mortality 30%). Therefore newer agents are required to manage post-transplant relapse in CML patients especially targeting the HSC compartment, particularly in AP.
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![Post relapse survival curve dichotomized by significantly associated factors **A)** disease status, **B)** type of relapse, **C)** time to diagnosis of relapse post-transplant, and **D)** pre-transplant TKI use.](nihms-630106-f0001){#F1}

![Hematopoietic progenitor cells numbers assessed and BCR-ABL transcript in hematopoietic progenitor cell compartment based on disease status of 45 time points from 36 patients. **A)** Distribution of absolute number of hematopoietic progenitor cells **B)** Distribution of BCR-ABL transcript in hematopoietic progenitor cell compartments.\
**Abbreviations:** HSC: hematopoietic stem cells; CMP: common myeloid progenitors, GMP: granulocyte- macrophage progenitors; CP: chronic phase; AP: advanced phase; MRD- : no minimal residual disease; TKI: control patients on TKI, who never received allo-SCT](nihms-630106-f0002){#F2}

![Representative data of BCR-ABL transcript levels in progenitor cell compartment and clinically monitored BCR-ABL values. **A)** CP with BCR-ABL transcript observed predominantly in the CMP or GMP compartment, **B**) CP with BCR-ABL transcript observed predominantly in the HSC compartment, **C)** AP with BCR-ABL transcript observed predominantly the CMP or GMP compartment, and **D**) AP with BCR-ABL transcript observed predominantly the HSC compartment. Abbreviations: HSC: HSC: hematopoietic stem cells; CMP: common myeloid progenitors, GMP: granulocyte- macrophage progenitors; DLI: donor lymphocyte infusion; TKI: tyrosine kinase inhibitors; 2^nd^ SCT: second allogeneic stem cell transplantation](nihms-630106-f0003){#F3}

![Kaplan Meier survival plot comparing post relapse survival in AP vs. CP according to the distribution of BCR-ABL transcript pattern in the progenitor cell compartment.\
**Abbreviations:** CP- undetectable: chronic phase patients with no detectable BCR-ABL transcript pattern; CP-HSC^+^ : chronic phase patients with BCR-ABL transcript pattern detected predominantly in hematopoietic stem cells; CP- CMP/GMP^+^ : chronic phase patients with BCRABL transcript pattern detected predominantly in common myeloid progenitors or granulocyte-macrophage progenitors; AP -- CMP/GMP^+^ : advanced phase patients with BCR-ABL transcript pattern detected predominantly in common myeloid progenitors or granulocyte-macrophage progenitors; AP-HSC^+^ : advanced phase patients with BCR-ABL transcript pattern detected predominantly in hematopoietic stem cells.](nihms-630106-f0004){#F4}

###### 

Characteristics of CML patients with relapse after allo-SCT

                                                 n, (%)
  ------------------------ --------------------- ---------------
  Sex                      Females               21 (36%)
                           Males                 38 (64%)
  Age\>40                  Yes                   25 (42%)
                           No                    34 (58%)
  Ethnicity                Blacks                4(7%)
                           Whites                13(22%)
                           Asian                 11(19%)
                           Hispanics             30(51%)
                           Unknown               1(1%)
  Disease status           AP                    18(30%)
                           CP                    41(70%)
  Pre-transplant TKI use   Yes                   12 (20%)
                           No                    47 (80%)
  Graft source             BM                    9 (15%)
                           PBSC                  50 (85%)
  Female to male           Yes                   15 (75%)
                           No                    44 (25%)
  Donor CMV                Negative              12 (20%)
                           Positive              47 (80%)
  Recipient CMV            Negative              9 (15%)
                           Positive              50 (85%)
  aGVHD                    Yes                   25 (42.4%)
                           No                    34 (57.6%)
  aGVHD grade II-IV        Yes                   17 (28.8%)
                           No                    42 (71.2%)
  cGVHD                    Yes                   36 (61%)
                           No                    23 (39%)
  Grade of cGVHD           Extensive             22 (37%)
                           Limited               14 (23%)
                           None                  23 (40%)
  IST\>3 years             Yes                   14 (24%)
                           No                    43 (73%)
                           Not available         2 (3%)
  Outcome                  Death                 20 (34%)
                           Alive                 39 (66%)
  Median time to death     Days (range)          671 (88-2908)
  Cause of death           Infection             3 (15%)
                           Relapse               16 (80%)
                           Respiratory failure   1 (5%)

Abbreviations: AP: Advanced phase; CP: Chronic phase; CMV: Cytomegalovirus BM: bone marrow; PBSC, peripheral blood stem cell; aGVHD: acute graft versus host disease; cGVHD: chronic graft versus host disease; IST: immunosuppressive therapy; TKI: tyrosine kinase inhibitor

###### 

Characteristics of relapsed CML patients after allo-SCT based on BCR-ABL transcript pattern

                                                       Persistently Negative (N= 26)   Persistently Positive (N= 33)   P value
  ------------------------------ --------------------- ------------------------------- ------------------------------- --------------
  Disease status                 AP                    5 ( 19%)                        13 (39%)                        0.15
                                 CP                    21 (81%)                        20 (61%)                        
  Pre-transplant TKI use         Yes                   3 (12%)                         9 (27%)                         0.20
                                 No                    23 (88%)                        24 (73%)                        
  Post relapse TKI               Yes                   17 (65%)                        17 (52%)                        0.30
                                 No                    9 (35%)                         16 (48%)                        
  Graft source                   BM                    5 (19%)                         4 (12%)                         0.49
                                 PBSC                  21 (81%)                        29 (88%)                        
  aGVHD grade II-IV              Yes                   9 (35%)                         8 (24%)                         0.40
                                 No                    17 (65%)                        25 (76%)                        
  cGVHD grade                    Extensive             11 (42%)                        11 (33%)                        0.22
                                 Limited               8 (31%)                         6 (18%)                         
                                 No                    7 (27%)                         16 (49%)                        
  IST\>3years                    Yes                   9 (35%)                         5 (15%)                         0.13
                                 No                    17 (65%)                        26 (85%)                        
  Relapse type                   Hematological         1 (4%)                          21 (64%)                        **\<0.001**
                                 Molecular             25 (96%)                        12 (36%)                        
  Outcome                        Death                 1 (4%) (1-AP)                   19 (58%) (12- AP; 7 CP)         **\<0.0001**
                                 Alive                 25 (96%)                        14(42%)                         
  Cause of death                 Relapse               0 (0%)                          16 (84%) (11-AP; 5CP)           0.051
                                 Infection             1 (100%)                        2 (11%) (2-CP)                  
                                 Respiratory failure   0 (0%)                          1 (5%) (1-AP)                   
  Median post relapse survival   3060 days             814 days                        **\<0.0001 (log-rank test)**    

Abbreviations: AP: Advanced phase; CP: Chronic phase; BM: bone marrow; PBSC, peripheral blood stem cell; aGVHD: acute graft versus host disease; cGVHD: chronic graft versus host disease; IST, immunosuppressive therapy; TKI: tyrosine kinase inhibitor

###### 

Multivariate analysis for post-relapse survival risk factors.

  Factors                             Model 1 (N=59 relapsed patients)   Model 2 (N=33 patients with persistent positive BCR-ABL)   Model 3 (N=22 patients with hematological relapse)                                    
  ----------------------------------- ---------------------------------- ---------------------------------------------------------- ---------------------------------------------------- ---------- --------------------- ---------
  Disease status at transplant (AP)   15.9 (4.7--53.8)                   \<0.001                                                    26.0 (6.3--107.7)                                    \<0.0001   11.8 (2.8 -- 50.3)    \<0.001
  Time to relapse \<100 days          10.2 (3.2-32.8)                    \<0.001                                                    5.3 (1.7-- 16.6)                                     0.004      2.5 (0.77 -- 7.9)     0.13
  Pre-transplant TKI use              0.17 (0.04--0.67)                  0.011                                                      0.08 (0.02 -- 0.34)                                  \<0.001    0.14 (0.03 -- 0.66)   0.012

Abbreviations: AP: Advanced phase; HR: hazard ratio; TKI: tyrosine kinase inhibitor
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